Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Therapeutics and Clinical Risk Management is Scopus-indexed (Q2, CiteScore 3.7), WoS SCIE, DOAJ. Published by Dove Medical Press Ltd.
Checked against the index lists dated .
ISSN 1176-6336Verify ISSN ↗1178-203XVerify ISSN ↗
Publisher: Dove Medical Press Ltd
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology, Toxicology and Pharmaceutics (all) | 24 / 79 | 70th | Q2 |
| Safety Research | 36 / 108 | 67th | Q2 |
| Pharmacology (medical) | 145 / 278 | 48th | Q3 |
| Chemical Health and Safety | 11 / 20 | 47th | Q3 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2006–present, best quartile Q2, CiteScore 3.7.
Therapeutics and Clinical Risk Management is Q2 in Pharmacology, Toxicology and Pharmaceutics (all) (rank 24 of 79), Q2 in Safety Research (rank 36 of 108) and Q3 in Pharmacology (medical) (rank 145 of 278), by CiteScore 2025. It is ranked in 4 subject areas in all.
Therapeutics and Clinical Risk Management is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 3.7, which places it in quartile Q2 at the 70th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.730, quartile Q1, with an H-index of 79.
The publisher lists an article processing charge of about US$2,836 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Therapeutics and Clinical Risk Management is published by Dove Medical Press Ltd. Its print ISSN is 1176-6336 and its online ISSN is 1178-203X.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal, listed in DOAJ.
Therapeutics and Clinical Risk Management has an h-index of 90 and a 2-year mean of 2.2 citations per paper (OpenAlex). Its Scopus CiteScore is 3.7, quartile Q2. On 2-year citations it ranks #27 of 77 Scopus journals in Pharmacology, Toxicology and Pharmaceutics (all).
Therapeutics and Clinical Risk Management published 162 papers in 2025; its busiest recent year was 2018 with 274. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 95 research articles (2025–2026), authors are most often from China (67.4%), Indonesia (8.4%) and Germany (2.4%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 8 retracted papers are recorded (3.2 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.